Literature DB >> 3470296

Effect of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D.

Z Darzynkiewicz, S P Carter, L J Old.   

Abstract

The tumor necrosis factor (TNF) exhibits a multitude of activities depending on the type of target cells. We characterized the cytostatic and cytotoxic effects of recombinant TNF, alone and in combination with actinomycin D (AMD), on the human leukemic cell line HL-60. Because HL-60 cells, when triggered to monocytic differentiation by phorbol esters, are known to produce and secrete TNF, their sensitivity to the factor could indicate an autocrine function of TNF in this cell system. Indeed, HL-60 cells were affected by TNF; their doubling time was increased by about 50% and progression through the cell cycle was perturbed. Initially, (up to 8 h) TNF induced a temporary arrest in G2 while later (24-48 h) it delayed progression through the G1 phase. Also, a transient increase in RNA content peaking at 6-8 h was apparent. The cytotoxicity of TNF alone was low. Thus, TNF may be involved in the regulation of the cell cycle of HL-60 cells during early stages of their differentiation. The cytotoxicity of TNF was markedly potentiated in the presence of AMD; the effect was AMD but not TNF concentration-dependent. Whereas at 20 and 50 ng/ml of AMD alone nonviable cells did not exceed 20% during the first 24 h of treatment, their proportion increased to 80 and 90%, respectively, in the presence of TNF. The most sensitive were cells in the S phase of the cell cycle. The observed synergistic effect of TNF and AMD does not appear to be caused by the action of TNF increasing the permeability of the cell membrane to AMD. The results indicate that HL-60 cells, ordinarily resistant to the cytotoxic action of TNF, can be rendered sensitive by treatment with AMD. This implies that a combination of TNF and AMD may be considered in oncology for treatment of tumors otherwise nonresponding to TNF alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470296     DOI: 10.1002/jcp.1041300304

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Stereoselective effects of 4-hydroxynonenal in cultured mouse hepatocytes.

Authors:  Michael J Dabrowski; Joseph K Zolnerciks; Larissa M Balogh; Robert J Greene; Terrance J Kavanagh; William M Atkins
Journal:  Chem Res Toxicol       Date:  2010-09-28       Impact factor: 3.739

2.  Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Authors:  J T Donaldson; T E Keane; S H Poulton; P J Walther
Journal:  Urol Res       Date:  1990

3.  Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

Authors:  P A van de Wiel; R H Pieters; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies.

Authors:  C B Powell; D G Mutch; L S Massad; M S Kao; J L Collins
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.

Authors:  Masamichi Ita; H Dorota Halicka; Toshiki Tanaka; Akira Kurose; Barbara Ardelt; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

6.  Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.

Authors:  Holly J Meany; Nita L Seibel; Junfeng Sun; Jerry Z Finklestein; Judith Sato; John Kelleher; Paul Sondel; Gregory Reaman
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

7.  Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.

Authors:  M Yanase; T Tsukamoto; Y Kumamoto; K Kato; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

8.  Comparison of the intoxication pathways of tumor necrosis factor and diphtheria toxin.

Authors:  M P Chang; B J Wisnieski
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.